Senator GALLAGHER (Australian Capital Territory—Minister for the Public Service, Minister for Finance, Minister for Women, Manager of Government Business in the Senate and Vice-President of the Executive Council) (14:12): I was just seeing if we had had any update from the health minister's office. I'm not aware of the date. I am aware that the government is working, as it would normally do— Senator McKenzie: Doesn't he read the papers? Senator GALLAGHER: Senator McKenzie asked, 'When did the government become aware?' and I'm saying that the minister for health— Senator McKenzie interjecting— The PRESIDENT: Senator McKenzie, it's not your question. Senator GALLAGHER: I don't think it's unreasonable to say that I don't have the exact date— Senator McKenzie interjecting— The PRESIDENT: Minister Gallagher, please resume your seat. Senator McKenzie interjecting— The PRESIDENT: Senator McKenzie! I have already called you to order. This is not your question. As I said to you yesterday, either sit in here in silence or leave the chamber—that's your choice. Please continue, Minister. Senator GALLAGHER: Thank you, President. I was just checking to see if we had an exact date, which was the actual question that I was asked. I will come back if I can provide that to you, but I am aware that the minister for health is across this and being briefed closely by his department on how to manage the shortage of IV fluids, and that is work that is being done across states and territories to manage the supply of IV fluids within their jurisdictions. The Commonwealth and the jurisdictions and other professional bodies have initiated a national IV fluid working group, which consists of state and territory representatives, private hospitals and the AMA, to work collaboratively on IV fluid supply issues and to co-ordinate the national response. There have been a number of outcomes to that meeting, which I am happy to go through, but we cannot compel sponsors to increase manufacturing for supply of medicines in Australia. However, the TGA monitors and mitigates medicine supply issues and has approved several alternative suppliers from overseas, under section 19A of the Therapeutic Goods Act 1989, to supplement the local production and supply of other registered products. The PRESIDENT: Senator Ruston, first supplementary?